ProQR Therapeutics BV (PRQR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $199.28M
Last updated: Nov 17, 2026 at 4:20 PM ET
ProQR Therapeutics BV (PRQR) Statistics
ProQR Therapeutics BV (PRQR) has a market cap of $199.28M. Its share count is up 28.32% from a year earlier.
Total Valuation
| Market Cap | $199.28M |
|---|---|
| Latest price (Nov 17, 2026) | $1.15 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Aug 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 7.0x and 2.4x. Its year-end P/S ranged from 10.7x to 715.8x from 2016 to 2025.
| P/S Ratio | 7.0x |
|---|---|
| P/B Ratio | 2.4x |
Price Statistics
The stock is down 47.00% over 52 weeks and trades 25.32% below its 50-day average.
| Beta (1Y) | 1.88 |
|---|---|
| 52-Week Change | -47.00% |
| 1-Month Change | -12.21% |
| 3-Month Change | -48.20% |
| 6-Month Change | -19.58% |
| 5-Year Change | -81.99% |
| 10-Year Change | -73.27% |
| Total Return (1Y) | -47.00% |
| Total Return (3Y CAGR) | -7.86% |
| Total Return (5Y CAGR) | -31.74% |
| Return vs SPY (1Y) | -56.27% |
| Max Drawdown (1Y) | -53.06% |
| Max Drawdown (3Y) | -75.06% |
| Sharpe Ratio (1Y) | -0.78 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $1.54 |
| 200-Day Average | $1.67 |
| 52-Week Range | $1.17 to $2.48 |
| RSI (14 Days) | 35.4 |
| Average Volume (20 Days) | 790.61K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.21x current liabilities.
| Current Ratio | 3.21x |
|---|---|
| Quick Ratio | 3.21x |
Returns and Efficiency
| Return on Assets (ROA) | -43.00% |
|---|---|
| ROE (5Y Average) | -59.72% |
| ROA (5Y Average) | -25.15% |
| ROIC (5Y Average) | -47.82% |
| Receivables Turnover | 7.23x |
Scores
PRQR has an Altman Z-Score of 1.41, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.41 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Growth
Revenue grew 61.99% a year over 3 years.
| Revenue Growth (3Y CAGR) | +61.99% |
|---|---|
| Revenue Growth (5Y CAGR) | +71.53% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PRQR
What is PRQR's market cap?
ProQR Therapeutics BV has a market cap of $199.28M.
How many shares of PRQR are outstanding?
ProQR Therapeutics BV has 141.23M shares outstanding. The count is up 28.32% from a year earlier.
Does PRQR pay a dividend?
No. ProQR Therapeutics BV does not pay a dividend.
PRQR pages: Overview, Charting, Financials, Statistics, Valuation, Competitors